Hellenic Army   Report issue

Academic/Hospital Phase 2 Phase 4
Founded: Greece (1821)

Organization Overview

First Clinical Trial
2012
NCT01572545
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

424 General Military Hospital, Thessaloniki, Greece | 424 military hospital of Thessaloniki, Greece | Dpt of Endocrinology & Diabetes, 251 Hellenic AirForce & VA General Hospital, Athens, Greece | Naval Hospital, Athens

Active Ingredients

Drugs in Phase 4 Trials (3)

alendronic acid (fosamax) (1 trial)

denosumab (prolia) (4 trials)

zoledronic acid (zometa) (2 trials)

Drugs in Phase 2 Trials (2)

hydrocortisone (solu-cortef) (1 trial)

vitamin c (1 trial)

Drugs in Other Trials (1)

hyaluronic acid (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Histiocytosis (Phase 2)

Histiocytosis, Langerhans-Cell (Phase 2)

Osteoporosis (Phase 4)

Osteoporosis, Postmenopausal (Phase 4)

Shock (Phase 2)

Shock, Septic (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 6
  • # of Trial APIs: 6